Enigmatig Reports 12.2% Revenue Growth and 68.8% Gross Margin in Fiscal 2025 Following NYSE American Listing
Enigmatig Reports 12.2% Revenue Growth and 68.8% Gross Margin in Fiscal 2025 Following NYSE American Listing
Enigmatig Signs MOU with TVA Capital to Empower SMEs for Sustainable Growth in Asia Pacific
Enigmatig Celebrates NYSE American Listing with Bell Ringing Ceremony, Signaling Next Phase of Global Growth
U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million
Enigmatig Limited Announces Closing of US$15 Million Initial Public Offering, Including Exercise of Over-allotment Option
Enigmatig Limited Announces Pricing of Initial Public Offering